Kymab Announces Abstracts to be Presented at the 24th EHA Annual Congress
  • Two Company sponsored abstracts will be presented
  • One oral presentation and one poster presentation

Cambridge, UK; May 16 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced that two abstracts describing KY1049, Kymab’s fully-human Factor VIII (FVIII)-mimetic bispecific antibody, will be presented at the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 13-16. An abstract containing a pre-clinical evaluation of Kymab’s proprietary FVIII-mimetic antibody will be presented as an oral presentation. A poster presentation introduces Kymab’s proprietary IntelliSelect® Bispecifics platform which can generate diverse and extensive panels of fully human, common light chain bispecific antibodies. Developed using high-throughput haemostatic assays, KY1049 is the first CLC bispecific molecule produced using the IntelliSelect® Bispecifics platform.

The abstracts have been published on the EHA website, and may be accessed via www.ehaweb.org.

List of Abstracts

Title: DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A
Topic: Bleeding disorders (congenital and acquired)
Session Title: Bleeding disorders (congenital and acquired)
Date: Friday, June 14
Time: 17:30 - 19:00
Location: Poster area
Final Abstract Code: PF338

Title: A FULLY HUMAN BISPECIFIC ANTIBODY FUNCTIONALLY RESCUES FACTOR VIII DEFICIENCY EX VIVO
Topic: Bleeding disorders (congenital and acquired)
Session Title: Novel insights to platelet and bleeding disorders
Date: Saturday, June 15
Time: 12:30 - 12:45
Location: Hall 3B
Final Abstract Code: S851

###ENDS###

Notes to Editors

About Kymab

Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of novel antibody-based therapies in a broad range of indications. The Company generates its product candidates using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s platforms have been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies allows for the identification of antibodies with optimal drug-like properties.
About IntelliSelect®

IntelliSelect® Transgenics platforms are designed to generate best-in-class, fully-human monoclonal antibodies from several highly-engineered strains of mice that have the complete constellation of human antibody building blocks in their genome.

The IntelliSelect® Screening technology combines single cell sequencing, genomics and proprietary bioinformatic algorithms to prioritize and select antibodies generated by IntelliSelect® Transgenics platforms that have the most desirable drug-like properties.

About IntelliSelect® Bispecifics

The IntelliSelect® Bispecifics platform is designed to generate, fully-human bispecific antibodies with naturally-paired common light chains from several highly-engineered strains of mice that have the complete constellation of human antibody heavy chain repertoire and one or more selected light chains.

The IntelliSelect® Bispecifics platform combines single cell sequencing, genomics and proprietary bioinformatic algorithms to prioritize and select antibodies generated by the IntelliSelect® Transgenics platforms that have the most desirable drug-like properties.

For more information please see http://www.kymab.com. Kymab is a trademark, and IntelliSelect® is a registered trademark, of Kymab Limited.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.